Paul M. Copeland MD

Voluntary Clinical Assistant Professor, General Internal Medicine

670 Albany St
Paul Copeland

General Internal Medicine


Dr. Paul Copeland, MD is an endocrinology, diabetes & metabolism specialist in Lynn, MA and has been practicing for 35 years. He graduated from Yale University in 1978 and specializes in endocrinology, diabetes & metabolism and internal medicine.


MD, Yale University, 1972

MPhil, Yale University, 1977

MA, Yale University, 1972


Published on 8/31/2022

Wexler DJ, Chang Y, Levy DE, Porneala B, McCarthy J, Rodriguez Romero A, Goldman V, Copeland PM, Steppel-Reznik J, Delahanty LM. Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trial. Obesity (Silver Spring). 2022 Oct; 30(10):1938-1950. PMID: 36046939.

Published on 2/12/2019

Fan X, Copeland P, Nawras S, Harrington A, Freudenreich O, Goff DC, Henderson DC. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology (Berl). 2019 Jun; 236(6):1949-1957. PMID: 30747254.

Published on 3/1/2018

Luo Y, Liu F, Natarajan R, Shukair N, Copeland P, Fan X. Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study. Int Clin Psychopharmacol. 2018 03; 33(2):88-91. PMID: 29084087.

Published on 11/22/2017

Nemani KL, Greene MC, Ulloa M, Vincenzi B, Copeland PM, Al-Khadari S, Henderson DC. Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. Clin Schizophr Relat Psychoses. 2019; 12(4):168-176. PMID: 29164928.

Published on 4/28/2015

Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015 May; 2(5):452-464. PMID: 26360288.

Published on 9/26/2014

Vincenzi B, Stock S, Borba CP, Cleary SM, Oppenheim CE, Petruzzi LJ, Fan X, Copeland PM, Freudenreich O, Cather C, Henderson DC. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophr Res. 2014 Nov; 159(2-3):395-403. PMID: 25261882.

Published on 5/1/2013

Vincenzi B, Borba CP, Gray DA, Copeland PM, Wang X, Fan X, Aragam GG, Henderson DC. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics. Ann Clin Psychiatry. 2013 May; 25(2):141-8. PMID: 23638445.

Published on 4/1/2013

Fan X, Liu E, Freudenreich O, Copeland P, Hayden D, Ghebremichael M, Cohen B, Ongur D, Goff DC, Henderson DC. No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia. J Clin Psychopharmacol. 2013 Apr; 33(2):226-30. PMID: 23422397.

Published on 2/21/2013

Li J, Li X, Liu E, Copeland P, Freudenreich O, Goff DC, Henderson DC, Song X, Fan X. No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia. Schizophr Res. 2013 May; 146(1-3):40-5. PMID: 23434504.

Published on 9/4/2012

Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand. 2013 Mar; 127(3):217-26. PMID: 22943577.

View full list of 43 publications.